The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

Biosimilar drugs are drugs that are a lot like biologics, but maybe not identical. Learn why this matters inside.

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Etanercept is a TNF (tumor necrosis factor) inhibitor used to treat several autoimmune conditions, including rheumatoid ...

Biosimilars could make healthcare more affordable—but here’s why activists are pushing for major revisions and greater ...

Daewoong Pharmaceutical said Tuesday that it has decided to launch a biosimilar business as the Korean traditional drug maker ...

Biocon Biologics, a subsidiary of Biocon, has introduced Nepexto, a biosimilar to Enbrel, in the Australian market for ...

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

The US Food and Drug Administration (FDA) announced the approval of 127 innovator and biosimilar drugs in 2024, a notable ...

SEOUL, July 29 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Tuesday it has been ...